Tag:
Roche
Latest Headlines
Latest Headlines
Biomarkers rescue Amgen's MAb, support Roche's Avastin
Studies give boost to Genentech/Roche's ($RHHBY) Avastin (bevacizumab) and Amgen's ($AMGN) rilotumumab.
Reuters: Drugmakers crafting emergency plan for Greece
Drugmakers are putting together a plan for how to keep medications flowing to Greece if the economy collapses and payments become uncertain.
GSK lands one-two punch in melanoma trial
Data from the small mid-stage trial provide early evidence that GSK's two-drug combo could have an edge over Roche's approved melanoma drug Zelboraf.
Cancer drug experts brace for ASCO abstract dump tonight
ASCO is releasing a mountain of data on cancer studies, and some of the biggest names in the business will be angling for star billing on some closely watched therapies.
Buzz: Big Pharma suitors line up for a look at Amylin's books
One of the cardinal rules involved in deal-making focuses on the need to get as many buyers to the negotiating table as possible. The next big rule: Make sure everyone knows who's interested in bidding.
Cancer drug developers angling for center stage at ASCO
Later this week the cancer drug research crowd will examine a tsunami of abstracts filed ahead of the ASCO meeting in early June in the hopes of finding a few gems.
Big Pharma's high-risk pursuit of CNS gold faces major market doubts
Here's an interesting number for anyone interested in the risks and rewards of drug development: Two of every three analysts and fund managers recently queried by the ISI Group say they expect that new Alzheimer's drugs in late-stage testing at Eli Lilly and Pfizer/J&J will fail.
Roche unit allies with genomics software group SoftGenetics
Roche's 454 Life Sciences has struck a partnership with SoftGenetics, a provider of next-generation sequencing (NGS) analytics. The co-op calls for Roche/454 and SoftGenetics to join forces in production promotions, the software company says.
FDA review questions long-term use of bone-building drugs
The FDA is giving women a lot to chew on with a new analysis of long-term use of drugs for osteoporosis because they can, although rarely, have a debilitating effect.
Roche's Tarceva wins NICE nod for first-line use
After an initial draft guidance rejecting the lung cancer treatment, the National Institute for Health and Clinical Excellence now says Tarceva should be available as a first-line treatment.
